HIGHLIGHTS
- who: (ADC)s and colleagues from the Sichuan Academy of Chinese Medicine Sciences, China Stanford University, United States have published the paper: A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer, in the Journal: (JOURNAL)
- what: A total of 39 (27%) of 147 patients experienced a treatment-emergent serious AE associated with the study drug and one patient with pneumonia was considered possibly treatment-related.
SUMMARY
To date, ADCs have been approved for breast cancer, lymphoma, multiple myeloma, and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.